Publications by the researcher in collaboration with Francisco Abad Santos (43)


  1. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19)

    Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1023-1033

  2. Author’s Response to: ‘Letter to the Editor in Response to: “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”’

    Advances in Therapy

  3. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 10, pp. 2051-2062

  4. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics

    Pharmacogenomics, Vol. 21, Núm. 10, pp. 663-675

  5. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers

    Pharmacogenomics Journal, Vol. 20, Núm. 2, pp. 235-245

  6. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 126, Núm. 3, pp. 236-246

  7. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates

    Biomedicines, Vol. 8, Núm. 4

  8. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

    BMC Pharmacology and Toxicology, Vol. 21, Núm. 1

  9. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran

    Advances in Therapy, Vol. 37, Núm. 8, pp. 3537-3550

  10. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects

    Clinical Drug Investigation, Vol. 40, Núm. 7, pp. 617-628